Quarterly Result6 Nov 2026, 09:24 pm
Kilitch Drugs Declares Unaudited Q2 FY27 Results
AI Summary
Kilitch Drugs India Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also approved the conversion of outstanding debt of up to ₹57.00 crore into equity shares of its subsidiary, Kilitch Estro Biotech PLC (KEB). Additionally, the company approved the divestment of its entire shareholding in KEB to HarmeeCare Pharmaceuticals for an aggregate consideration of USD 14.00 million, which includes settlement of KEB's existing debts and liabilities. The transaction is subject to regulatory approvals.
Key Highlights
- Unaudited standalone and consolidated financial results for Q2 FY27 declared.
- Board approved conversion of ₹57 crore debt in subsidiary to equity.
- Company approved divestment of subsidiary for USD 14 million.
- Transaction subject to regulatory approvals and compliances.
Price Impact
More from KILITCH